Subtle cognitive decline and biomarker staging in preclinical Alzheimer’s disease

Manuscript Number: 


Mark W. Bondi, Lisa Delano-Wood, Emily C. Edmonds, Douglas Galasko, David P. Salmon


Mark W. Bondi

  • Nothing to Disclose

Lisa Delano-Wood

  • Nothing to Disclose

Emily C. Edmonds

  • Nothing to Disclose

Douglas Galasko

  • Consulting Fees:
    Serve on Data Safety Monitoring Boards for clinical trials for Balance Pharmaceuticals, Inc; Astra-Zeneca, Inc; Neotope Pharmaceuticals. Consultant for TransTech Pharmaceuticals, Inc

David P. Salmon

  • Consulting Fees:
    ad hoc consultant for Bristol Myer Squibb